Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 28, 2013; 19(44): 8071-8077
Published online Nov 28, 2013. doi: 10.3748/wjg.v19.i44.8071
Published online Nov 28, 2013. doi: 10.3748/wjg.v19.i44.8071
Shugan-decoction relieves visceral hyperalgesia and reduces TRPV1 and SP colon expression
Jing-Juan Shang, Hui Xu, Rong-Zhu Tang, Yue-Bin Dong, Division of Gastroenterology, Shanghai Seventh People’s Hospital, Shanghai 200137, China
Jian-Ye Yuan, Jian-Qun Xie, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Author contributions: Shang JJ and Yuan JY designed the study, performed the experiments and wrote the manuscript; Xu H, Tang RZ and Dong YB provided vital reagents and analytical tools and edited the manuscript for intellectual content; Xie JQ provided financial support and intellectual guidance in study design and data interpretation; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81072786; the Innovation Program of the Shanghai Municipal Education Commission, No. 12YZ065; and the Longhua Medical Project, No. D-09
Correspondence to: Jian-Qun Xie, Professor, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China. xiejianqun@live.cn
Telephone: +86-21-51322090 Fax: +86-21-51322001
Received: July 5, 2013
Revised: September 28, 2013
Accepted: October 19, 2013
Published online: November 28, 2013
Revised: September 28, 2013
Accepted: October 19, 2013
Published online: November 28, 2013
Core Tip
Core tip: The classical rat model of chronic stress induction via water avoidance stress (WAS) test was used to investigate the therapeutic effect of the Shugan-decoction (SGD) on visceral hypersensitivity of the gastrointestinal tract and its underlying molecular mechanisms. The study design reflected the therapeutic potential of SGD for treating the stress-related gut aspects of irritable bowel syndrome (IBS) in humans. Mid- and high-dose SGD treatments significantly increased the WAS-reduced pressure thresholds, similarly to those induced by the IBS drug dicetel. The SGD treatments also restored WAS-related changes in transient receptor potential vanilloid 1 and substance P expression in the colon.